Veradermics, Inc(MANE)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
MANE Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Veradermics, Inc (MANE), a Healthcare sector company. MANE is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Veradermics, Inc reports net income of $-23.5M, free cash flow of $-14.5M. Top institutional holders of MANE by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT, FMR, SR ONE CAPITAL MANAGEMENT, based on the most recent SEC filings. MANE trades on the NYSE exchange and files with the SEC under CIK 1827635. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MANE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Veradermics, Inc directly from SEC EDGAR.
Net Income
Q2 2026
$-23.5M
Free Cash Flow
Q2 2026
$-14.5M
ROIC
Q2 2026
-14.5%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-164.3% YoYOperating Income
-170.2% YoYEPS (Diluted)
-202.1% YoYTotal Assets
+174.8% YoYOp. Cash Flow
-202.3% YoYFree Cash Flow
-202.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Net Income | $-70.0M -164.3% | $-26.5M | — |
| Operating Income | $-72.3M -170.2% | $-26.8M | — |
| EPS (Diluted) | $-111.91 -202.1% | $-37.05 | — |
| Total Assets | $152.6M +174.8% | $55.5M | — |
| Operating Cash Flow | $-71.6M -202.3% | $-23.7M | — |
| Free Cash Flow | $-71.6M -202.4% | $-23.7M | — |
Get alerted when MANE's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Veradermics, Inc including:
Top Institutional Holders of MANE
SUVRETTA CAPITAL MANAGEMENT, LLC
$512.5M4,168,970 shFMR LLC
$394.0M3,204,981 shSR ONE CAPITAL MANAGEMENT, LP
$295.3M2,401,868 shDeep Track Capital, LP
$245.9M2,000,000 shCITADEL ADVISORS LLC
$230.9M1,877,775 shSiren, L.L.C.
$203.5M1,655,374 shBlackRock, Inc.
$195.9M1,593,791 shVIKING GLOBAL INVESTORS LP
$192.0M1,561,494 shJPMORGAN CHASE & CO
$144.2M1,165,584 shabrdn plc
$134.8M1,096,642 sh
| Fund | Value | Shares |
|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | $512.5M | 4,168,970 |
| FMR LLC | $394.0M | 3,204,981 |
| SR ONE CAPITAL MANAGEMENT, LP | $295.3M | 2,401,868 |
| Deep Track Capital, LP | $245.9M | 2,000,000 |
| CITADEL ADVISORS LLC | $230.9M | 1,877,775 |
| Siren, L.L.C. | $203.5M | 1,655,374 |
| BlackRock, Inc. | $195.9M | 1,593,791 |
| VIKING GLOBAL INVESTORS LP | $192.0M | 1,561,494 |
| JPMORGAN CHASE & CO | $144.2M | 1,165,584 |
| abrdn plc | $134.8M | 1,096,642 |
More Healthcare Companies
View all Healthcare →Put MANE on your watchlist
Track score changes the day Veradermics, Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MANE a good stock to buy?
13F Pro's AI-powered analysis of Veradermics, Inc (MANE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MANE are available on the MANE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MANE is classified as a mid company.
Which hedge funds own MANE?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MANE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Veradermics, Inc's investment landscape.